CSIMarket



Worst Performing Stocks In Medical Laboratories Industry Over The Past 12 Months



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares are up by 14.05% on average, in Medical Laboratories Industry over the past 12 months.

Here are the Worst performing stocks in Medical Laboratories Industry.




ACON

$0.299

$-10.1010 -97.13%
Last 12 Months


ACON

$0.299

$-10.1010 -97.13%



Aclarion Inc

Aclarion Inc stock dropped -97.13% over the past 12 months.


Aclarion Inc is a technology company that operates on a software-as-a-service (SaaS) business model. They provide their customers with cloud-based solutions, enabling them to streamline and automate their business processes efficiently. Aclarion offers a range of customizable software solutions, including data management, project management, and collaboration tools, tailored to meet the specific needs of their clients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.627 mill. $ 0.060 mill. $ -6.127 mill. 5 mill. - Y/Y -60.29 %
Market Cap. Revenues TTM Net Income TTM

$ 1.627 mill.


$ 0.060 mill.


$ -6.127 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.29 %


MRQ Y/Y - %



RNLX

$0.349

$-3.5110 -90.96%
Last 12 Months


RNLX

$0.349

$-3.5110 -90.96%



Renalytix Plc

Renalytix Plc stock dropped -90.96% over the past 12 months.


Renalytix Plc is a biotechnology company that focuses on developing and commercializing diagnostic tests for kidney disease. Their business model centers around using advanced biomarkers and artificial intelligence to enhance the accuracy and speed of identifying kidney disease, ultimately improving patient outcomes. Renalytix aims to provide healthcare professionals with innovative tools that enable personalized treatments and reduce the overall burden of kidney disease on individuals and healthcare systems.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 33.074 mill. $ 6.832 mill. $ -101.037 mill. 95 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 33.074 mill.


$ 6.832 mill.


$ -101.037 mill.

Employees Shares Outstanding P/E

-


95 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ISPC

$0.3078

$-1.0822 -77.86%
Last 12 Months


ISPC

$0.3078

$-1.0822 -77.86%



Ispecimen inc

Ispecimen Inc shares went down -77.86% over the past 12 months.


iSpecimen Inc*s business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.811 mill. $ 9.268 mill. $ -11.570 mill. 9 mill. - Y/Y -22.38 %
Market Cap. Revenues TTM Net Income TTM

$ 2.811 mill.


$ 9.268 mill.


$ -11.570 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -22.38 %


MRQ Y/Y - %



GPFT

$0.0012

$-0.0035 -74.47%
Last 12 Months


GPFT

$0.0012

$-0.0035 -74.47%



Grapefruit Usa Inc

Grapefruit Usa Inc shares went down -74.47% over the past 12 months.


Grapefruit USA Inc operates as a fully licensed cannabis distribution and manufacturing company. They focus on producing premium, high-quality cannabis products and efficiently distributing them to licensed retailers in the United States.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.688 mill. $ 0.035 mill. $ -4.367 mill. 574 mill. - Y/Y -98.07 %
Market Cap. Revenues TTM Net Income TTM

$ 0.688 mill.


$ 0.035 mill.


$ -4.367 mill.

Employees Shares Outstanding P/E

-


574 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -98.07 %


MRQ Y/Y - %



LUNA

$2.96

$-6.1200 -67.40%
Last 12 Months


LUNA

$2.96

$-6.1200 -67.40%



Luna Innovations Inc

Luna Innovations Inc shares went down -67.40% over the past 12 months.


Luna Innovations Inc*s business model involves providing advanced technology solutions and services to various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 104.247 mill. $ 113.692 mill. $ -1.781 mill. 35 mill. - Y/Y 17.07 %
Market Cap. Revenues TTM Net Income TTM

$ 104.247 mill.


$ 113.692 mill.


$ -1.781 mill.

Employees Shares Outstanding P/E

236


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 17.07 %


MRQ Y/Y - %



CNTG

$0.5151

$-0.9649 -65.20%
Last 12 Months


CNTG

$0.5151

$-0.9649 -65.20%



Centogene N v

Centogene N V stock dropped -65.20% over the past 12 months.


Centogene N v operates in the field of rare genetic diseases, offering genetic testing and diagnostics services to patients, healthcare providers, and pharmaceutical companies. Their business model involves leveraging their extensive knowledge and expertise in genetic analysis and interpreting data to provide accurate diagnoses and personalized treatment options for individuals with rare genetic disorders. Additionally, they collaborate with pharmaceutical companies to assist in drug development and clinical trials for rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.411 mill. $ 54.319 mill. $ -39.796 mill. 28 mill. - Y/Y 2.16 %
Market Cap. Revenues TTM Net Income TTM

$ 14.411 mill.


$ 54.319 mill.


$ -39.796 mill.

Employees Shares Outstanding P/E

500


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2.16 %


MRQ Y/Y - %



OPGN

$3.2

$-5.4000 -62.79%
Last 12 Months


OPGN

$3.2

$-5.4000 -62.79%



Opgen Inc

Opgen Inc shares declined -62.79% over the past 12 months.


OpGen Inc*s business model revolves around providing molecular diagnostic solutions and informatics services to combat global healthcare challenges, particularly in the field of infectious diseases. They develop innovative technologies that assist healthcare professionals in identifying, treating, and preventing the spread of infectious pathogens.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.261 mill. $ 2.673 mill. $ -26.659 mill. 1 mill. - Y/Y -81.59 %
Market Cap. Revenues TTM Net Income TTM

$ 4.261 mill.


$ 2.673 mill.


$ -26.659 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -81.59 %


MRQ Y/Y - %



NOTV

$2.25

$-2.6700 -54.27%
Last 12 Months


NOTV

$2.25

$-2.6700 -54.27%



Inotiv Inc

Inotiv Inc shares dropped -54.27% over the past 12 months.


Inotiv Inc is a contract research organization (CRO) that provides preclinical and nonclinical research services to the pharmaceutical, biotechnology, and medical device companies. The company offers a range of services including drug discovery, safety assessment, toxicology testing, and analytical services. By assisting clients with their research and development needs, Inotiv aims to contribute to the advancement of medicine and the development of new treatment options.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 58.120 mill. $ 552.744 mill. $ -71.368 mill. 26 mill. - Y/Y -21.41 %
Market Cap. Revenues TTM Net Income TTM

$ 58.120 mill.


$ 552.744 mill.


$ -71.368 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -21.41 %


MRQ Y/Y - %



EXAS

$46.36

$-52.2800 -53.00%
Last 12 Months


EXAS

$46.36

$-52.2800 -53.00%



Exact Sciences Corporation

Exact Sciences Corporation stock went down -53.00% over the past 12 months.


Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 8,453.746 mill. $ 2,573.276 mill. $ -240.226 mill. 182 mill. - Y/Y 6.77 %
Market Cap. Revenues TTM Net Income TTM

$ 8,453.746 mill.


$ 2,573.276 mill.


$ -240.226 mill.

Employees Shares Outstanding P/E

5,361


182 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.77 %


MRQ Y/Y - %



LWLG

$3.69

$-4.1500 -52.93%
Last 12 Months


LWLG

$3.69

$-4.1500 -52.93%



Lightwave Logic Inc

Lightwave Logic Inc shares went down -52.93% over the past 12 months.


Lightwave Logic Inc*s business model is focused on developing and commercializing advanced photonic devices and technologies for various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 438.928 mill. $ 0.030 mill. $ -21.778 mill. 119 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 438.928 mill.


$ 0.030 mill.


$ -21.778 mill.

Employees Shares Outstanding P/E

10


119 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PMD

$2.37

$-2.5950 -52.27%
Last 12 Months


PMD

$2.37

$-2.5950 -52.27%



Psychemedics Corporation

Psychemedics Corporation stock declined -52.27% over the past 12 months.


Psychemedics Corp*s business model is focused on providing hair drug testing services to corporate clients, law enforcement agencies, and individuals. They collect hair samples, conduct extensive laboratory analysis, and deliver accurate and confidential drug test results to their customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.760 mill. $ 20.676 mill. $ -4.458 mill. 6 mill. - Y/Y -12.58 %
Market Cap. Revenues TTM Net Income TTM

$ 13.760 mill.


$ 20.676 mill.


$ -4.458 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -12.58 %


MRQ Y/Y - %



BFLY

$1.17

$-1.2000 -50.63%
Last 12 Months


BFLY

$1.17

$-1.2000 -50.63%



Butterfly Network Inc

Butterfly Network Inc stock dropped -50.63% over the past 12 months.


Butterfly Network Inc*s business model involves developing and providing handheld ultrasound devices that are portable, affordable, and user-friendly. Their products aim to revolutionize medical imaging and provide accessible healthcare solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 244.382 mill. $ 67.656 mill. $ -121.921 mill. 209 mill. - Y/Y 11.63 %
Market Cap. Revenues TTM Net Income TTM

$ 244.382 mill.


$ 67.656 mill.


$ -121.921 mill.

Employees Shares Outstanding P/E

-


209 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 11.63 %


MRQ Y/Y - %



FLGT

$20.95

$-18.1800 -46.46%
Last 12 Months


FLGT

$20.95

$-18.1800 -46.46%



Fulgent Genetics Inc

Fulgent Genetics Inc stock declined -46.46% over the past 12 months.


Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 628.772 mill. $ 285.288 mill. $ -64.981 mill. 30 mill. - Y/Y -20.64 %
Market Cap. Revenues TTM Net Income TTM

$ 628.772 mill.


$ 285.288 mill.


$ -64.981 mill.

Employees Shares Outstanding P/E

284


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -20.64 %


MRQ Y/Y - %



NRC

$23.52

$-18.7900 -44.41%
Last 12 Months


NRC

$23.52

$-18.7900 -44.41%



National Research Corporation

National Research Corporation stock went down -44.41% over the past 12 months.


National Research Corporation (NRC) operates as a healthcare research and performance measurement firm, providing insights and data-driven solutions. They collect, analyze, and interpret patient and healthcare provider feedback to assist organizations in improving their overall quality of care. NRC*s business model focuses on selling research products, licensing data services, and providing consulting solutions to healthcare organizations seeking to enhance patient experiences and outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 563.610 mill. $ 147.420 mill. $ 30.366 mill. 24 mill. 18.93 Y/Y -3.18 %
Market Cap. Revenues TTM Net Income TTM

$ 563.610 mill.


$ 147.420 mill.


$ 30.366 mill.

Employees Shares Outstanding P/E

-


24 mill.


18.93

Revenue Growth Income Growth

MRQ Y/Y -3.18 %


MRQ Y/Y -8.69 %



NNOX

$8.91

$-7.0000 -44.00%
Last 12 Months


NNOX

$8.91

$-7.0000 -44.00%



Nano x Imaging Ltd

Nano X Imaging Ltd shares went down -44.00% over the past 12 months.


Nano X Imaging Ltd is a medical imaging technology company that aims to revolutionize the field by developing and commercializing a novel digital X-ray system. Their business model involves building partnerships with healthcare providers, imaging equipment manufacturers, and distributors to bring their innovative technology to market, providing cost-effective and accessible diagnostic solutions globally. By delivering high-quality imaging at a fraction of the cost of traditional systems, Nano X Imaging aims to improve healthcare outcomes and increase patient access to effective diagnostics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 502.239 mill. $ 9.905 mill. $ -60.776 mill. 56 mill. - Y/Y 15.47 %
Market Cap. Revenues TTM Net Income TTM

$ 502.239 mill.


$ 9.905 mill.


$ -60.776 mill.

Employees Shares Outstanding P/E

-


56 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 15.47 %


MRQ Y/Y - %



VRDN

$13.89

$-7.5300 -35.15%
Last 12 Months


VRDN

$13.89

$-7.5300 -35.15%



Viridian Therapeutics Inc

Viridian Therapeutics Inc stock dropped -35.15% over the past 12 months.


Viridian Therapeutics Inc is a biotechnology company that focuses on developing novel therapeutics to treat various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 848.666 mill. $ 0.288 mill. $ -218.125 mill. 61 mill. - Y/Y -26.53 %
Market Cap. Revenues TTM Net Income TTM

$ 848.666 mill.


$ 0.288 mill.


$ -218.125 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -26.53 %


MRQ Y/Y - %



XGN

$1.93

$-0.8800 -31.32%
Last 12 Months


XGN

$1.93

$-0.8800 -31.32%



Exagen Inc

Exagen Inc shares went down -31.32% over the past 12 months.


Exagen Inc*s business model revolves around providing diagnostic testing solutions in the field of autoimmune diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 34.633 mill. $ 55.733 mill. $ 4.295 mill. 18 mill. - Y/Y 28.36 %
Market Cap. Revenues TTM Net Income TTM

$ 34.633 mill.


$ 55.733 mill.


$ 4.295 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 28.36 %


MRQ Y/Y - %



CHEK

$2.04

$-0.6600 -24.44%
Last 12 Months


CHEK

$2.04

$-0.6600 -24.44%



Check cap Ltd

Check Cap Ltd stock declined -24.44% over the past 12 months.


Check Cap Ltd is a medical technology company that develops and commercializes an ingestible imaging capsule that allows for the detection and monitoring of colorectal polyps. Their business model revolves around manufacturing and selling this capsule device while also providing associated services and support to healthcare professionals and patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.931 mill. $ - mill. $ 17.568 mill. 6 mill. 0.68 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 11.931 mill.


$ - mill.


$ 17.568 mill.

Employees Shares Outstanding P/E

-


6 mill.


0.68

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y -8.06 %



PSNL

$1.66

$-0.5300 -24.20%
Last 12 Months


PSNL

$1.66

$-0.5300 -24.20%



Personalis Inc

Personalis Inc shares dropped -24.20% over the past 12 months.


Personalis Inc*s business model revolves around offering advanced genomic sequencing and data analysis solutions to empower researchers and healthcare providers in their efforts to develop precision medicine and personalized therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 80.833 mill. $ 70.528 mill. $ -112.780 mill. 49 mill. - Y/Y 22.81 %
Market Cap. Revenues TTM Net Income TTM

$ 80.833 mill.


$ 70.528 mill.


$ -112.780 mill.

Employees Shares Outstanding P/E

-


49 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.81 %


MRQ Y/Y - %



MDXH

$2.79

$-0.8400 -23.14%
Last 12 Months


MDXH

$2.79

$-0.8400 -23.14%



Mdxhealth Sa

Mdxhealth Sa shares dropped -23.14% over the past 12 months.


MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 72.439 mill. $ 70.193 mill. $ -43.100 mill. 26 mill. - Y/Y 89.43 %
Market Cap. Revenues TTM Net Income TTM

$ 72.439 mill.


$ 70.193 mill.


$ -43.100 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 89.43 %


MRQ Y/Y - %



VCYT

$22.75

$-5.7700 -20.23%
Last 12 Months


VCYT

$22.75

$-5.7700 -20.23%



Veracyte Inc

Veracyte Inc stock dropped -20.23% over the past 12 months.


Veracyte Inc*s business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,700.785 mill. $ 375.473 mill. $ -68.177 mill. 75 mill. - Y/Y 17.50 %
Market Cap. Revenues TTM Net Income TTM

$ 1,700.785 mill.


$ 375.473 mill.


$ -68.177 mill.

Employees Shares Outstanding P/E

677


75 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 17.50 %


MRQ Y/Y - %



GH

$31.07

$-7.7700 -20.01%
Last 12 Months


GH

$31.07

$-7.7700 -20.01%



Guardant Health Inc

Guardant Health Inc stock went down -20.01% over the past 12 months.


Guardant Health Inc*s business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,781.592 mill. $ 603.725 mill. $ -460.901 mill. 122 mill. - Y/Y 30.90 %
Market Cap. Revenues TTM Net Income TTM

$ 3,781.592 mill.


$ 603.725 mill.


$ -460.901 mill.

Employees Shares Outstanding P/E

1,100


122 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.90 %


MRQ Y/Y - %



ENZ

$1.16

$-0.2700 -18.88%
Last 12 Months


ENZ

$1.16

$-0.2700 -18.88%



Enzo Biochem Inc

Enzo Biochem Inc shares dropped -18.88% over the past 12 months.


Enzo Biochem Inc operates as a biotechnology company that specializes in the development and commercialization of innovative diagnostic and research products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 59.179 mill. $ 32.466 mill. $ 32.566 mill. 51 mill. 0.00 Y/Y -47.65 %
Market Cap. Revenues TTM Net Income TTM

$ 59.179 mill.


$ 32.466 mill.


$ 32.566 mill.

Employees Shares Outstanding P/E

412


51 mill.


0.00

Revenue Growth Income Growth

MRQ Y/Y -47.65 %


MRQ Y/Y - %



HALB

$0.0074

$-0.0012 -13.95%
Last 12 Months


HALB

$0.0074

$-0.0012 -13.95%



Halberd Corporation

Halberd Corporation shares went down -13.95% over the past 12 months.


Halberd Corporation*s business model focuses on providing a range of products or services to meet specific industries* needs, with a targeted approach and a customer-centric approach.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.795 mill. $ 23.914 mill. $ 35.330 mill. 513 mill. 0.00 Y/Y -99.99 %
Market Cap. Revenues TTM Net Income TTM

$ 3.795 mill.


$ 23.914 mill.


$ 35.330 mill.

Employees Shares Outstanding P/E

-


513 mill.


0.00

Revenue Growth Income Growth

MRQ Y/Y -99.99 %


MRQ Y/Y - %



MXCT

$4.49

$-0.5400 -10.74%
Last 12 Months


MXCT

$4.49

$-0.5400 -10.74%



Maxcyte inc

Maxcyte Inc stock declined -10.74% over the past 12 months.


Maxcyte Inc*s business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 467.363 mill. $ 44.054 mill. $ -36.567 mill. 104 mill. - Y/Y 32.25 %
Market Cap. Revenues TTM Net Income TTM

$ 467.363 mill.


$ 44.054 mill.


$ -36.567 mill.

Employees Shares Outstanding P/E

-


104 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 32.25 %


MRQ Y/Y - %



OABI

$4.48

$-0.5000 -10.04%
Last 12 Months


OABI

$4.48

$-0.5000 -10.04%



Omniab Inc

Omniab Inc shares declined -10.04% over the past 12 months.


Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 451.382 mill. $ 21.046 mill. $ -63.480 mill. 101 mill. - Y/Y -77.53 %
Market Cap. Revenues TTM Net Income TTM

$ 451.382 mill.


$ 21.046 mill.


$ -63.480 mill.

Employees Shares Outstanding P/E

-


101 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -77.53 %


MRQ Y/Y - %



GNOM

$11.27

$-1.2100 -9.70%
Last 12 Months


GNOM

$11.27

$-1.2100 -9.70%



Complete Genomics Inc

Complete Genomics Inc shares went down -9.70% over the past 12 months.


Complete Genomics Inc operates in the field of genetic sequencing, offering end-to-end solutions for large-scale genomic research. They provide comprehensive DNA sequencing services, including sample preparation, sequencing, data analysis, and consulting, primarily catering to research institutions, pharmaceutical companies, and academic organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 386.952 mill. $ 19.877 mill. $ -57.048 mill. 34 mill. - Y/Y -62.39 %
Market Cap. Revenues TTM Net Income TTM

$ 386.952 mill.


$ 19.877 mill.


$ -57.048 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -62.39 %


MRQ Y/Y - %



LH

$206.17

$-5.5700 -2.63%
Last 12 Months


LH

$206.17

$-5.5700 -2.63%



Laboratory Corporation Of America Holdings

Laboratory Corporation Of America Holdings stock dropped -2.63% over the past 12 months.


Laboratory Corporation Of America Holdings operates as a leading healthcare diagnostics company. They offer a range of clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model focuses on providing accurate and timely test results, enabling healthcare professionals to diagnose, treat, and monitor patients effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17,474.632 mill. $ 11,560.300 mill. $ 434.200 mill. 85 mill. 41.65 Y/Y -15.92 %
Market Cap. Revenues TTM Net Income TTM

$ 17,474.632 mill.


$ 11,560.300 mill.


$ 434.200 mill.

Employees Shares Outstanding P/E

75,500


85 mill.


41.65

Revenue Growth Income Growth

MRQ Y/Y -15.92 %


MRQ Y/Y 7.03 %



HOLX

$77.69

$-1.5900 -2.01%
Last 12 Months


HOLX

$77.69

$-1.5900 -2.01%



Hologic Inc

Hologic Inc shares declined -2.01% over the past 12 months.


Hologic Inc*s business model revolves around the development, manufacturing, and commercialization of medical technology and diagnostic products, primarily focused on women*s healthcare. They aim to provide innovative solutions for various medical specialties, including breast and skeletal health, gynecological health, and surgical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 18,456.192 mill. $ 4,046.300 mill. $ 621.900 mill. 238 mill. 29.65 Y/Y -0.85 %
Market Cap. Revenues TTM Net Income TTM

$ 18,456.192 mill.


$ 4,046.300 mill.


$ 621.900 mill.

Employees Shares Outstanding P/E

6,944


238 mill.


29.65

Revenue Growth Income Growth

MRQ Y/Y -0.85 %


MRQ Y/Y -22.24 %



GEHC

$80.28

$-1.1200 -1.38%
Last 12 Months


GEHC

$80.28

$-1.1200 -1.38%



Ge Healthcare Technologies Inc

Ge Healthcare Technologies Inc shares declined -1.38% over the past 12 months.


GE Healthcare Technologies Inc*s business model is focused on providing innovative medical devices, healthcare information technology, and healthcare services to improve patient care and outcomes. The company offers a wide range of products and solutions in areas such as medical imaging, patient monitoring, diagnostics, and healthcare IT. They also collaborate with healthcare providers and partners to offer integrated solutions and support throughout the entire healthcare ecosystem.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 36,848.520 mill. $ 16,328.000 mill. $ 1,619.000 mill. 459 mill. 23.49 Y/Y -1.50 %
Market Cap. Revenues TTM Net Income TTM

$ 36,848.520 mill.


$ 16,328.000 mill.


$ 1,619.000 mill.

Employees Shares Outstanding P/E

-


459 mill.


23.49

Revenue Growth Income Growth

MRQ Y/Y -1.50 %


MRQ Y/Y 1.31 %



IQV

$224.17

$4.5400 2.07%
Last 12 Months


IQV

$224.17

$4.5400 2.07%



Iqvia Holdings Inc

Iqvia Holdings Inc stock went up 2.07% over the past 12 months.


IQVIA Holdings Inc is a multinational company that operates in the healthcare industry. Its business model revolves around providing advanced analytics, technology solutions, and clinical research services to help clients make informed decisions, optimize their operations, and accelerate drug development. By leveraging its vast data resources and expertise, IQVIA aims to support healthcare professionals in improving patient outcomes and driving innovation in the industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 41,314.531 mill. $ 15,069.000 mill. $ 1,357.000 mill. 184 mill. 30.48 Y/Y 2.33 %
Market Cap. Revenues TTM Net Income TTM

$ 41,314.531 mill.


$ 15,069.000 mill.


$ 1,357.000 mill.

Employees Shares Outstanding P/E

79,000


184 mill.


30.48

Revenue Growth Income Growth

MRQ Y/Y 2.33 %


MRQ Y/Y -0.35 %



DGX

$144.11

$3.3300 2.37%
Last 12 Months


DGX

$144.11

$3.3300 2.37%



Quest Diagnostics Inc

Quest Diagnostics Inc stock improved 2.37% over the past 12 months.


Quest Diagnostics Inc operates as a provider of clinical laboratory and diagnostic information services, serving patients, physicians, hospitals, and pharmaceutical companies. The company generates revenue by offering a range of diagnostic testing services, including laboratory analysis, test development, and specialized diagnostics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16,140.320 mill. $ 9,287.000 mill. $ 899.000 mill. 112 mill. 19.44 Y/Y 1.50 %
Market Cap. Revenues TTM Net Income TTM

$ 16,140.320 mill.


$ 9,287.000 mill.


$ 899.000 mill.

Employees Shares Outstanding P/E

49,000


112 mill.


19.44

Revenue Growth Income Growth

MRQ Y/Y 1.50 %


MRQ Y/Y -4.15 %



INCY

$63.66

$1.7200 2.78%
Last 12 Months


INCY

$63.66

$1.7200 2.78%



Incyte Corporation

Incyte Corporation shares increased 2.78% over the past 12 months.


Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. Their business model revolves around extensive research and development efforts to identify potential drug candidates for various diseases. With a focus on oncology and other serious inflammatory conditions, Incyte aims to bring effective therapies to patients while collaborating with partners and leveraging their extensive intellectual property portfolio.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14,464.762 mill. $ 3,767.865 mill. $ 745.444 mill. 227 mill. 19.35 Y/Y 8.93 %
Market Cap. Revenues TTM Net Income TTM

$ 14,464.762 mill.


$ 3,767.865 mill.


$ 745.444 mill.

Employees Shares Outstanding P/E

2,094


227 mill.


19.35

Revenue Growth Income Growth

MRQ Y/Y 8.93 %


MRQ Y/Y 681.22 %



CRL

$216.19

$7.0300 3.36%
Last 12 Months


CRL

$216.19

$7.0300 3.36%



Charles River Laboratories International inc

Charles River Laboratories International Inc stock increased 3.36% over the past 12 months.


Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,207.722 mill. $ 4,111.596 mill. $ 450.898 mill. 52 mill. 25.42 Y/Y -1.73 %
Market Cap. Revenues TTM Net Income TTM

$ 11,207.722 mill.


$ 4,111.596 mill.


$ 450.898 mill.

Employees Shares Outstanding P/E

20,000


52 mill.


25.42

Revenue Growth Income Growth

MRQ Y/Y -1.73 %


MRQ Y/Y -28.35 %



CSTL

$18.55

$2.3500 14.51%
Last 12 Months


CSTL

$18.55

$2.3500 14.51%



Castle Biosciences Inc

Castle Biosciences Inc stock went up 14.51% over the past 12 months.


Castle Biosciences Inc is a biotechnology company that specializes in the development and commercialization of diagnostic tests for specialized cancers. Their business model revolves around leveraging molecular diagnostic technologies to provide physicians with personalized, actionable information when making treatment decisions for patients with difficult-to-diagnose or higher-risk cancers. By offering these tests, Castle Biosciences aims to improve patient outcomes and contribute to the advancement of precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 509.847 mill. $ 250.725 mill. $ -0.132 mill. 27 mill. - Y/Y 73.59 %
Market Cap. Revenues TTM Net Income TTM

$ 509.847 mill.


$ 250.725 mill.


$ -0.132 mill.

Employees Shares Outstanding P/E

200


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 73.59 %


MRQ Y/Y - %



PHG

$26.68

$3.9100 17.17%
Last 12 Months


PHG

$26.68

$3.9100 17.17%



Koninklijke Philips Nv

Koninklijke Philips Nv stock increased 17.17% over the past 12 months.


Koninklijke Philips Nv operates as a diversified technology company, focusing on areas such as healthcare, consumer lifestyle, and lighting. The company provides a wide range of products and solutions, including medical imaging equipment, home appliances, personal care products, and lighting solutions. Philips Nv*s business model involves innovation-driven research and development, strategic partnerships, and a global distribution network to deliver its products and services to customers worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24,378.196 mill. $ 20,349.280 mill. $ -518.560 mill. 914 mill. - Y/Y 1.92 %
Market Cap. Revenues TTM Net Income TTM

$ 24,378.196 mill.


$ 20,349.280 mill.


$ -518.560 mill.

Employees Shares Outstanding P/E

82,000


914 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 1.92 %


MRQ Y/Y - %



AMS

$3.27

$0.7000 27.24%
Last 12 Months


AMS

$3.27

$0.7000 27.24%



American Shared Hospital Services

American Shared Hospital Services shares improved 27.24% over the past 12 months.


American Shared Hospital Services (ASHS) operates a unique business model by providing state-of-the-art medical equipment on a shared basis to hospitals and medical centers across the United States. They establish partnerships with healthcare providers, offering the latest technology for radiation therapy, radiosurgery, and nuclear medicine without the need for significant capital investments. By leveraging their expertise and established relationships in the healthcare industry, ASHS delivers cost-effective solutions that benefit both patients and healthcare facilities alike.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.504 mill. $ 20.562 mill. $ 0.230 mill. 7 mill. 38.96 Y/Y 4.43 %
Market Cap. Revenues TTM Net Income TTM

$ 21.504 mill.


$ 20.562 mill.


$ 0.230 mill.

Employees Shares Outstanding P/E

-


7 mill.


38.96

Revenue Growth Income Growth

MRQ Y/Y 4.43 %


MRQ Y/Y -35.00 %



ICLR

$336.03

$87.0400 34.96%
Last 12 Months


ICLR

$336.03

$87.0400 34.96%



Icon Plc

Icon Plc shares increased 34.96% over the past 12 months.


Icon Plc is a leading provider of clinical research services, specializing in the design and management of clinical trials for pharmaceutical and biotechnology companies. Their business model focuses on offering a comprehensive range of services, including study design, data management, regulatory support, and statistical analysis, to support the development of new drugs and medical devices. Icon Plc*s success lies in its ability to provide customized solutions to its clients, efficiently navigate the regulatory landscape, and consistently deliver high-quality and timely results.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 27,795.609 mill. $ 8,120.176 mill. $ 1,236.802 mill. 83 mill. 45.41 Y/Y 4.89 %
Market Cap. Revenues TTM Net Income TTM

$ 27,795.609 mill.


$ 8,120.176 mill.


$ 1,236.802 mill.

Employees Shares Outstanding P/E

15,950


83 mill.


45.41

Revenue Growth Income Growth

MRQ Y/Y 4.89 %


MRQ Y/Y 144.76 %



BIAF

$2.56

$0.8000 45.45%
Last 12 Months


BIAF

$2.56

$0.8000 45.45%



Bioaffinity Technologies Inc

Bioaffinity Technologies Inc shares went up 45.45% over the past 12 months.


Bioaffinity Technologies Inc is a biotechnology company specializing in developing and commercializing diagnostics for various medical conditions. They utilize their patented platform technology, Affinity?, which enables the detection of cancer and other diseases at an early stage through the use of biomarkers. The company focuses on licensing their technology and partnering with diagnostic companies, aiming to provide accurate, non-invasive, and cost-effective diagnostic solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.383 mill. $ 4.938 mill. $ -8.366 mill. 10 mill. - Y/Y 261,180.24 %
Market Cap. Revenues TTM Net Income TTM

$ 25.383 mill.


$ 4.938 mill.


$ -8.366 mill.

Employees Shares Outstanding P/E

-


10 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 261,180.24 %


MRQ Y/Y - %



BDSX

$1.69

$0.5300 45.69%
Last 12 Months


BDSX

$1.69

$0.5300 45.69%



Biodesix Inc

Biodesix Inc stock improved 45.69% over the past 12 months.


Biodesix Inc is a biotechnology company that utilizes advanced diagnostics to develop personalized medicine solutions for improving patient outcomes. Their business model involves leveraging their proprietary blood-based tests and data analytics to assist healthcare providers in making informed treatment decisions. By partnering with pharmaceutical companies and healthcare institutions, Biodesix aims to commercialize their innovative solutions and drive adoption in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 134.708 mill. $ 44.026 mill. $ -63.345 mill. 80 mill. - Y/Y 21.46 %
Market Cap. Revenues TTM Net Income TTM

$ 134.708 mill.


$ 44.026 mill.


$ -63.345 mill.

Employees Shares Outstanding P/E

-


80 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 21.46 %


MRQ Y/Y - %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com